AACR 2025 | BlissBio to Present 4 ADC Posters at the 2025 AACR Annual Meeting

2025-04-28

HONG KONG, China, April 28, 2025 – BlissBio announces today 4 posters of anti-tumor antibody-drug conjugate (ADC) preclinical study results will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25 to 30, 2025, in McComick Place Convention Center, Chicago, IL, U.S.

BlissBio Receives IND Approval from FDA for Novel ADC BB-1712

2024-10-17

October 16, 2024 US Time --- BlissBio announced that its investigational new drug (IND) application of an innovative antibody-drug conjugate (ADC) BB-1712 was approved by the U.S. Food and Drug Administration (FDA). BB-1712, a B7-H3 targeted ADC with Eribulin as its toxin, is developed for the treatment of multiple solid tumors.

ESMO 2024 | BlissBio to Present Phase II Clinical Data of ADC BB-1701 at ESMO Congress 2024

2024-09-11

September 11, 2024 – BlissBio announces today the Phase II clinical data of antibody-drug conjugate (ADC) BB-1701 will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, which will be held in Barcelona, Spain from September 13 to 17.

ASCO 2024 | BlissBio to Present Phase I Clinical Data of Anti-tumor Drug BB-1701 at the 2024 ASCO Annual Meeting

2024-06-01

HANGZHOU, China, June 1, 2024 – BlissBio announces today the Phase I clinical data of Anti-tumor antibody-drug conjugate (ADC) BB-1701 will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..

BLISS BIOPHARMACEUTICAL TO PRESENT DATA ON BB-1701 COHORT EXPANSION OF PHASE I STUDY AT 2023 ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

2023-12-06

BLISS BIOPHARMACEUTICAL TO PRESENT DATA ON BB-1701 COHORT EXPANSION OF PHASE I STUDY AT 2023 ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

BlissBio Completes Series B++ Financing, Invested by Eisai

2023-06-07

HANGZHOU, June 06, 2023 --- Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”) announced the completion of Series B++ financing invested by Eisai Co., Ltd (“Eisai”).